Whereas MYCN is amplified and highly expressed in about one-third of high-risk neuroblastomas, MYC is highly expressed in a distinct subset of Stage 4 neuroblastomas that have similarly aggressive clinical behavior (6). This evidence concerns the gene MYCN and neuroblastoma.